drugset / Trial / NCT02251600

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

NCT02251600

Phase 1 Completed 24 enrolled PTC Therapeutics
NaSingle-groupOpen-labelBasic science

Summary

Study to characterize the single-state and steady-state dosing of oral deflazacort in pediatric and adolescents subjects.

Timeline

Start
2014-12
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Deflazacort Other / unclassified 0.9 mg/kg Oral